Cyprumed Enters Agreement with Ferring Pharmaceuticals
Development of Oral Drug Delivery Technology for Patient-Centric non-invasive Peptide Therapeutics
31-Jan-2022 -
Cyprumed GmbH announced that it has entered into a research and early development agreement with Ferring Pharmaceuticals for the development of next generation formulation technology for non-invasive delivery of biologics, with a focus on oral peptide delivery. Peptides and other large molecular ...
biologics
drug delivery
peptide therapeutics